# A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Source: https://onco.cc/trials/nct07372625/  
OnCo record `nct07372625` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Rezatapopt run by PMV Pharmaceuticals, Inc, now recruiting.

## Summary

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. is a phase 1 interventional study registered as NCT07372625 by PMV Pharmaceuticals, Inc, with 14 participants planned, started 2026-02-04, primary completion expected 2027-03. Conditions recorded: TP53 Y220C Mutation, Advanced Solid Tumors. Interventions recorded: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07372625
- Phase: 1
- Setting: A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
- Sponsor: PMV Pharmaceuticals, Inc
- Enrolled: 14

## Sources

- ClinicalTrials.gov NCT07372625: https://clinicaltrials.gov/study/NCT07372625

## Connected records

- drugs: [Rezatapopt](https://onco.cc/drugs/rezatapopt/)
- companies: [PMV Pharma](https://onco.cc/companies/pmv-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct07372625.json